Viatris (VTRS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of ...

The recent update to Viatris centers on a refreshed US$16 price target, set against a fair value estimate that has inched from about US$12.44 to roughly US$12.67 as the affordable medicines theme ...

Fintel reports that on January 16, 2026, Argus Research upgraded their outlook for Viatris (NasdaqGS:VTRS) from Hold to Buy.

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...

The market expects Viatris (VTRS) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook is ...

Viatris (NASDAQ:VTRS) shares fell in the premarket on Friday after the company announced that its experimental therapy for blepharitis, an inflammatory condition of the eyelids, did not reach the main ...

On December 5, 2025, Viatris Inc. held its annual meeting of shareholders to elect directors, approve executive compensation, and ratify its accounting firm. The meeting resulted in the election of ...